新規キャップ依存性エンドヌクレアーゼ阻害薬 S-033188 および
新規シデロフォアセファロスポリン抗菌薬 cefiderocol の学会発表について
－米国感染症学会週間（IDWeek 2017）にて臨床および非臨床試験結果を発表－

塩野義製薬株式会社（本社：大阪市中央区、代表取締役社長：手代木 功）は、当社が創製し開発を進めている新規キャップ依存性エンドヌクレアーゼ阻害薬 S-033188 および新規注射用シデロフォアセファロスポリン抗菌薬 cefiderocol（一般名、開発番号：S-649266）につきまして、臨床試験および非臨床試験結果を米国カリフォルニア州サンディエゴで10月4日～8日に開催予定の米国感染症学会週間 Infectious Disease Week 2017（以下「IDWeek 2017」）において発表しますので、お知らせいたします。

IDWeek 2017において予定している発表の概要は、次のとおりです。

<table>
<thead>
<tr>
<th>セッション名</th>
<th>講演題目</th>
<th>発表情報</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expanded Spectrum · New Antimicrobial Susceptibility Testing</td>
<td>Synergistic Antiviral Activity of S-033188/S-033447, a Novel Inhibitor of Influenza Virus Cap-Dependent Endonuclease, in Combination with Neuraminidase Inhibitors</td>
<td>Poster number: 1214, Friday, October 6, 2017 12:30 p.m. – 2:00 p.m. Poster Hall CD</td>
</tr>
<tr>
<td>Preclinical Study with New Antibiotics and Antifungals</td>
<td>Delayed Dosing Of S-033188, a Novel Inhibitor of Influenza Virus Cap-Dependent Endonuclease, Exhibited Significant Reduction of Viral Titer and Mortality in Mice Infected with Influenza A Virus</td>
<td>Poster number: 1514, Friday, October 6, 2017 12:30 p.m. – 2:00 p.m. Poster Hall CD</td>
</tr>
<tr>
<td>Late Breaker Oral Abstracts</td>
<td>Cap-Dependent Endonuclease Inhibitor S-033188 for the Treatment of Influenza: Results from a Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Study in Otherwise Healthy Adolescents and Adults with Seasonal Influenza</td>
<td>Saturday, October 7, 2017 10:40 AM Room: 02</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>セッション名</th>
<th>講演題目</th>
<th>発表情報</th>
</tr>
</thead>
<tbody>
<tr>
<td>HAI: MDRO-GNR/Emerging Resistant Bacterial Pathogens</td>
<td>National Prevalence and Regional Variation of Carbapenem-Resistant Gram-Negative Bacteria in the Ambulatory and Acute Care Settings in the United States in 2016</td>
<td>Poster number: 371, Thursday, October 5, 2017 12:30 p.m. – 2:00 p.m. Poster Hall CD</td>
</tr>
<tr>
<td></td>
<td>Burden of Carbapenem-Resistant Gram-Negative Infections in US Hospitals</td>
<td>Poster number: 374, Thursday, October 5, 2017 12:30 p.m. – 2:00 p.m. Poster Hall CD</td>
</tr>
</tbody>
</table>
Friday, October 6, 2017  
12:30 p.m. – 2:00 p.m.  
Poster Hall CD |
| --- | --- | --- |
|  | In Vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates Collected from Urinary Tract Source: SIDERO-WT-2014/SIDERO-WT-2015 | Poster number: 1229  
Friday, October 6, 2017  
12:30 p.m. – 2:00 p.m.  
Poster Hall CD |
| Preclinical Study with New Antibiotics and Antifungals | In Vivo Efficacy of Cefiderocol Against Carbapenem-Resistant Gram-Negative Bacilli in Murine Urinary Tract Infection Models | Poster number: 1512  
Friday, October 6, 2017  
12:30 p.m. – 2:00 p.m.  
Poster Hall CD |
|  | In Vivo Efficacy of Humanized Exposures of Cefiderocol Compared with Cefepime (FEP) and Meropenem (MEM) Against Gram-Negative Bacteria in a Murine Thigh Model | Poster number: 1520  
Friday, October 6, 2017  
12:30 p.m. – 2:00 p.m.  
Poster Hall CD |
|  | Good Correlation of Cefiderocol Between In Vivo Efficacy Murine Thigh/Lung Infection Models and MIC Determined in Iron-Depleted Conditions | Poster number: 1524  
Friday, October 6, 2017  
12:30 p.m. – 2:00 p.m.  
Poster Hall CD |
| Clinical Study with New Antibiotics and Antifungals | Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol in Subjects without Infection and Patients with Complicated Urinary Tract Infection and Acute Uncomplicated Pyelonephritis | Poster number: 1831  
Saturday, October 7, 2017  
12:30 p.m. – 2:00 p.m.  
Poster Hall CD |
|  | Clinical Response of Cefiderocol Compared with Imipenem/Cilastatin in the Treatment of Adults With Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Uncomplicated Pyelonephritis: Results from a Multicenter, Double-Blind, Randomized Study (APEKS'-cUTI) | Poster number: 1869  
Saturday, October 7, 2017  
12:30 p.m. – 2:00 p.m.  
Poster Hall CD |

以上

[お問合せ先]
塩野義製薬株式会社 広報部
TEL：06-6209-7885  FAX：06-6229-9596